You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
沃森生物(300142.SZ)半年度淨利潤降27.6%至6149.11萬元 擬10派0.2元
格隆匯 08-14 20:54

格隆匯 8 月 14日丨沃森生物(300142.SZ)發佈2020年半年度報告,實現營業收入5.73億元,同比增長14.57%;歸屬於上市公司股東的淨利潤6149.11萬元,同比減少27.60%;歸屬於上市公司股東的扣除非經常性損益後的淨利潤5734.50萬元,同比下降29.32%;基本每股收益0.04元,擬每10股派發現金紅利0.2元(含税)。

2020年上半年,子公司玉溪沃森獲批簽發產品數量合計2214.5193萬劑(瓶),較上年同期增長25.58%

報告期內,公司集中優勢資源,全力推進已處於臨牀研究和產業化關鍵階段的各在研產品的研究和產業化進度。2020110日,公司收到了國家藥監局頒發的13價肺炎結合疫苗《藥品註冊批件》,330日首批產品獲得批簽發,422日實現首針接種。公司二價HPV疫苗於20204月完成了III期臨牀研究並獲得了《臨牀試驗報告》,615日收到二價HPV疫苗申報生產的《受理通知書》,目前,該疫苗申報生產的相關評審工作正在進行中。九價HPV疫苗目前正在開展I期臨牀試驗。公司與合作方共同合作開發的新型冠狀病毒mRNA疫苗於20206月收到國家藥品監督管理局批准的《藥物臨牀試驗批件》,目前正在開展I期臨牀試驗。公司其他處於臨牀研究和臨牀前研究階段的在研產品的研發工作按計劃持續推進。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account